(CIA) Citizens - Ratings and Ratios
LifeInsurance, WholeLife, Endowment, CriticalIllness, AccidentHealth
CIA EPS (Earnings per Share)
CIA Revenue
Description: CIA Citizens
Citizens Inc (NYSE:CIA) is an insurance holding company operating in the life insurance sector, both domestically and internationally, through two main segments: Life Insurance and Home Service Insurance. The Life Insurance segment primarily targets non-U.S. residents with U.S. dollar-denominated insurance products, while the Home Service Insurance segment focuses on serving middle- and lower-income households in specific U.S. regions.
With a presence in the life and health insurance sub-industry, Citizens Inc has a market capitalization of $179.04 million, indicating a relatively modest size. The companys price-to-earnings ratio stands at 21.00, with a forward P/E of 16.42, suggesting some potential for earnings growth. The return on equity (RoE) is 5.01%, which, while not exceptionally high, is a positive indicator of the companys ability to generate profits from shareholders equity.
To further analyze Citizens Incs performance, we can consider additional key performance indicators (KPIs). For instance, the companys revenue growth rate, insurance penetration, and policy retention rates could provide insights into its operational efficiency and competitiveness. The ratio of total benefits paid to total premiums collected could also be an important metric, as it reflects the companys ability to manage its insurance liabilities effectively. Moreover, examining the companys investment portfolio and its yield could offer a glimpse into its asset management capabilities and potential for generating non-premium income.
From a valuation perspective, comparing Citizens Incs price-to-book ratio to that of its industry peers could help determine if the stock is undervalued or overvalued relative to its assets. Additionally, analyzing the companys dividend yield and payout ratio could be relevant for income-focused investors, as it may indicate the sustainability of dividend payments. Overall, a comprehensive evaluation of Citizens Incs financials, operational metrics, and industry positioning is necessary to form a well-informed investment decision.
Additional Sources for CIA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
CIA Stock Overview
Market Cap in USD | 200m |
Sector | Financial Services |
Industry | Insurance - Life |
GiC Sub-Industry | Life & Health Insurance |
IPO / Inception | 1988-12-05 |
CIA Stock Ratings
Growth Rating | -31.1 |
Fundamental | 46.7 |
Dividend Rating | 0.0 |
Rel. Strength | 20.1 |
Analysts | - |
Fair Price Momentum | 3.17 USD |
Fair Price DCF | 3.06 USD |
CIA Dividends
Currently no dividends paidCIA Growth Ratios
Growth Correlation 3m | -29.4% |
Growth Correlation 12m | 6% |
Growth Correlation 5y | -56.6% |
CAGR 5y | -7.22% |
CAGR/Max DD 5y | -0.10 |
Sharpe Ratio 12m | 0.34 |
Alpha | 20.64 |
Beta | 1.750 |
Volatility | 52.81% |
Current Volume | 120.2k |
Average Volume 20d | 143k |
Stop Loss | 3.7 (-5.4%) |
As of August 03, 2025, the stock is trading at USD 3.91 with a total of 120,187 shares traded.
Over the past week, the price has changed by -4.40%, over one month by +8.31%, over three months by -3.93% and over the past year by +45.35%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Citizens (NYSE:CIA) is currently (August 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 46.71 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CIA is around 3.17 USD . This means that CIA is currently overvalued and has a potential downside of -18.93%.
Citizens has no consensus analysts rating.
According to our own proprietary Forecast Model, CIA Citizens will be worth about 3.8 in August 2026. The stock is currently trading at 3.91. This means that the stock has a potential downside of -2.81%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 5 | 27.9% |
Analysts Target Price | - | - |
ValueRay Target Price | 3.8 | -2.8% |